Investigations of the efficacy of diphenylcyclopropenone immunotherapy for the treatment of warts

Suh, Dong-Woo; Lew, Bark‐Lynn; Sim, Woo‐Young

doi:10.1111/ijd.12688

Cited by 20 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This response rate was, however, not achieved until a period around six months later. The mechanism of action involved is best described as an immunomodulatory effect caused by a type IV contact allergic response in the viral lesion .…”

Section: Cutaneous Wartsmentioning

confidence: 99%

“…Electrocautery: Electrosurgical ablation with a wire loop is simple to perform and, according to the studies available, on a par with lasers. The average clearance rate stands at 85 %, the rate of recurrence at 14–22 % . However, these studies do not take into consideration that large clusters of condylomata acuminata have to be treated multiple times within 2–3 months, and attempts to treat, for example, an area of 30 cm² with hundreds of condylomata acuminata in a single session (using a laser or electrocautery) are usually unsuccessful and lead to recurrence.…”

Section: Genital Wartsmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic management of cutaneous and genital warts

Ockenfels

2016

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryDuring their lifetime, at least 10 % of the population will be infected by human papillomaviruses (HPV), clinically characterized by the formation of cutaneous or genital warts. Although warts are ubiquitous, there are no defined treatments. Especially in the first six months, warts frequently resolve without therapeutic intervention. This complicates the interpretation of study data, given that many studies do not differentiate between newly infected patients and those with infections that have persisted for a long time. Similarly, most studies do not take location, size, and thickness of lesions into account, either. The objective of the present review article is to analyze the study data currently available, taking into consideration both subtypes and locations -factors exceedingly crucial in clinical practice. In particular, the distinction between new-onset and chronic recalcitrant warts is reflected in a therapeutic algorithm. In the case of genital warts, the algorithm is more clearly determined by the extent of the area affected rather than the longevity of lesions. In immunocompetent individuals, any therapeutic intervention must be aimed at achieving complete resolution.

show abstract

Section: Cutaneous Wartsmentioning

confidence: 99%

Section: Genital Wartsmentioning

confidence: 99%

Therapeutic management of cutaneous and genital warts

Ockenfels

2016

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…When DPCP immunotherapy is performed for the treatment of warts, variable factors including age, sex, disease duration, location, number and size of warts, and susceptibility to sensitization by DPCP might be associated with the efficacy of treatments. The sensitizing ability, cure rate, and duration of DPCP treatment for warts have been reported in previous studies . However, there has been no study of factors contributing to the duration of treatment with DPCP immunotherapy for periungual warts, which could predict the course of treatment.…”

Section: Introductionmentioning

confidence: 95%

Factors contributing to the treatment duration of diphenylcyclopropenone immunotherapy for periungual warts

Park

Kim

2015

Dermatologic Therapy

View full text Add to dashboard Cite

Diphenylcyclopropenone (DPCP) immunotherapy has been shown to be efficacious for the treatment of warts, especially periungual warts for which destructive techniques are limited. However, factors affecting the duration of treatment of periungual warts have not been studied. A total of 61 patients with periungual warts who were completely cured with DPCP immunotherapy were included in this study. Age, sex, disease duration, location (fingernail, toenail, or both), number of warts, diameter of the largest wart, application number for sensitization and two types of sensitization reactions, erythema and blister index (EBI), and pruritus index were evaluated. Multiple linear regression analysis was performed to find correlations of these variables with the treatment duration. Of the nine variables, application number for sensitization (regression coefficient = 3.251 and 2.428, respectively) and EBI (regression coefficient = -9.950 and -9.694, respectively) were independent factors significantly affecting both the total duration of treatment and the duration of treatment after sensitization (p < 0.05, respectively). The sample size was limited. A shorter sensitization period and more severe EBI of the sensitization reaction contribute to a shorter time required for a complete cure in the treatment of periungual warts with DPCP immunotherapy.

show abstract

“…Suh et al performed an uncontrolled, open-label study which showed DPCP to have a clearance rate as high as 82.9% [11]. Imiquimod was shown to have a success rate of 44%, ranging from 27% to 89% in an evidencebased review performed by Ahn and Huang [12].…”

Section: Efficacy Of Contact Immunotherapies and Contact Allergensmentioning

confidence: 99%

Wart Immunotherapies: A Short Review

Sefcik¹,

Burkhart²

2017

TODJ

View full text Add to dashboard Cite

Objective:To review the efficacy and costs of various contact immunotherapies, contact allergens, intralesional immunotherapies, and intralesional cytotoxic agents for the treatment of recalcitrant warts. Background:Cutaneous warts are common viral skin lesions caused by human papillomavirus that can be challenging to treat and frustrating for physicians and patients. Although several treatment options exist, there is no single treatment that can ensure a complete response with lack of lesion recurrence. Immunotherapies for recalcitrant warts present as a cost-effective, efficient therapy option for patients. Intralesional approaches have the added benefit of affecting warts at locations distant to the target location by inducing a systemic Tcell mediated response in the body. Results:Various contact immunotherapies, contact allergens, intralesional immunotherapies, and intralesional cytotoxic agents have shown to be effective in treating warts. The costs of each treatment varies drastically from around $10 US to over $1000 US to achieve a complete response. Several antigens were found to be both efficacious and cost effective. Conclusion:Although efficacy of several antigens has been confirmed by randomized studies, more randomized comparative studies will need to be performed in order to determine the best antigen and correct standardized doses for the treatment of warts in individual patients. It is important to note that individual response to antigen type and dose may vary among patients. Therefore, further studies may play an important role in the use of immunotherapies in a clinical setting.

show abstract

Investigations of the efficacy of diphenylcyclopropenone immunotherapy for the treatment of warts

Abstract: Immunotherapy with DPCP is an effective and well-tolerated option for the treatment of recalcitrant warts.

Cited by 20 publications

References 16 publications

Therapeutic management of cutaneous and genital warts

Therapeutic management of cutaneous and genital warts

Factors contributing to the treatment duration of diphenylcyclopropenone immunotherapy for periungual warts

Wart Immunotherapies: A Short Review

Contact Info

Product

Resources

About